5 Fabulous Exercises You Can Do Anytime, Anywhere!
Have you ever wondered how to stay active without having to make time to go to the gym or go for a run? Check…
This study is for individuals with very high levels of triglycerides (a type of fatty substance in the blood). This is called severe hypertriglyceridemia. Individuals are thought to have this condition when their blood triglyceride levels are above 500 mg/dL.
Participants in this study will start taking either a once-weekly investigational injection or placebo. The investigational med is called pegozafermin and is currently not approved by the FDA. In previous studies, Pegozafermin has shown the ability to lower blood triglycerides and decrease abnormal fat storage in the liver. Participants have a 75% chance of receiving pegozafermin or a 25% chance of receiving placebo.
The purpose of this study is to learn about the safety and effectiveness of the research drug on triglyceride levels, cholesterols, fatty proteins, blood sugars, and organs like the liver.
To take part in the study, participants should be:
CEO and Medical Director
Director of Clinical Services
Director of Clinical Research
Clinical Research Coordinator
Clinical Research Coordinator
Navigator/Study Start-up Manager
Clinical Research Coordinator
Clinical Research Coordinator